基于家庭的年龄相关性黄斑变性监测系统的经济学评价
该经济学分析模拟了Medicare合格患者接受家庭每日视野监测系统与常规护理相比的长期效果,使用AREDS2家庭眼监测研究、Wills眼科医院治疗与延伸研究及AREDS1数据。结果显示,对单眼已有脉络膜新生血管或双眼多个风险因素的患者,监测具有成本效果;对低风险患者则通常不具有成本效果。
要点
- 家庭远程监测在单眼已有CNV或双眼多个风险因素的患者中具有成本效果。
- 监测使联邦政府10年内每人花费1312美元(95%CI,222-2848美元)。
- 对低风险患者(无或少量风险因素),监测通常不具有成本效果。
核心结论
- 与仅定期检查相比,对存在CNV风险的AMD患者进行家庭远程监测具有成本效果。
- 对单眼已有CNV的患者进行监测可节省成本,但对低风险患者(包括无或少量风险因素者)监测通常不具有成本效果。
- 在Medicare覆盖下,监测会给政府带来预算支出,但对AMD高风险患者可节省成本。
- 如果监测能降低定期检查频率或减少一次或多次雷珠单抗注射,则可能对社会节省成本。
研究设计与样本
- 本研究为经济学分析,采用模拟方法评估家庭每日视野监测系统的潜在成本、成本效果及政府预算影响。
- 模拟纳入符合条件的高危湿性AMD Medicare患者,使用AREDS2家庭眼监测研究的效果与视力结局数据、Wills眼科医院治疗与延伸研究的治疗数据及AREDS1的AMD进展数据。
- 采用单因素和概率敏感性分析,并使用治疗与延伸研究对照组结局的替代情景来检验数据与假设的不确定性。
主要发现
- 对单眼已有CNV或双眼多个CNV风险因素(大玻璃膜疣和视网膜色素异常)的患者进行远程监测,净终生社会成本为907美元(95%CI,-6302至2809美元)。
- 从联邦政府角度,监测使每名患者在10年内花费1312美元(95%CI,222至2848美元)。
- 增量成本效果比为每获得一个质量调整生命年35663美元(95%CI,从成本节省至235613美元)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Medicare recently approved coverage of home telemonitoring for early detection of incident choroidal neovascularization (CNV) among patients with age-related macular degeneration (AMD), but no economic evaluation has yet assessed its cost-effectiveness and budgetary impact. OBJECTIVES: To evaluate a home-based daily visual-field monitoring system using simulation methods and to apply the findings of the Home Monitoring of the Eye study to the US population at high risk for wet-form AMD. DESIGN, SETTING, AND PARTICIPANTS: In this economic analysis, an evaluation of the potential cost, cost-effectiveness, and government budgetary impact of adoption of a home-based daily visual-field monitoring system among eligible Medicare patients was performed. Effectiveness and visual outcomes data from the Age-Related Eye Disease Study 2 Home Monitoring of the Eye study, treatment data from the Wills Eye Hospital Treat & Extend study, and AMD progression data from the Age-Related Eye Disease Study 1 were used to simulate the long-term effects of telemonitoring patients with CNV in one eye or large drusen and/or pigment abnormalities in both eyes. Univariate and probabilistic sensitivity analysis and an alternative scenario using the Treat & Extend study control group outcomes were used to examine uncertainty in these data and assumptions. INTERVENTIONS: Home telemonitoring of patients with AMD for early detection of CNV vs usual care. MAIN OUTCOMES AND MEASURES: Incremental cost-effectiveness ratio, net present value of lifetime societal costs, and 10-year nominal government expenditures. RESULT: Telemonitoring of patients with existing unilateral CNV or multiple bilateral risk factors for CNV (large drusen and retinal pigment abnormalities) incurs $907 (95% CI, -$6302 to $2809) in net lifetime societal costs, costs $1312 (95% CI, $222-$2848) per patient during 10 years from the federal government's perspective, and results in an incremental cost-effectiveness ratio of $35 663 (95% CI, cost savings to $235 613) per quality-adjusted life-year gained. CONCLUSIONS AND RELEVANCE: Home telemonitoring of patients with AMD who are at risk for CNV was cost-effective compared with scheduled examinations alone. Monitoring patients with existing CNV in one eye is cost saving, but monitoring is generally not cost-effective among patients with low risk of CNV, including those with no or few risk factors. With Medicare coverage, monitoring incurs budgetary expenditures for the government but is cost-saving for patients at high risk of AMD. Monitoring could be cost saving to society if monitoring reduced the frequency of scheduled examinations or led to a reduction of one or more injections of ranibizumab.
引用
- Wittenborn JS, Clemons T, Regillo C, et al. Economic Evaluation of a Home-Based Age-Related Macular Degeneration Monitoring System. JAMA Ophthalmol. 2017. PMID: 28358948. doi:10.1001/jamaophthalmol.2017.0255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。